undamentalytics Newsletter
Sign in

Medpace Holdings, Inc. income statement

In fiscal 2025, Medpace Holdings, Inc. reported revenue of $2.53bn, up 20.0% on the year before, operating income of $535m (a 21.1% margin) and net income of $451m, or $15.28 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue3594224367058619261,1421,4601,8862,1092,5302,838
Selling, general and administrative576263769592108131161180198193
Operating income215265101127167199279337447535607
Income before tax−8225794125169202283336476542627
Income tax19182124232037537291109
Net income−9133973100145182245283404451518
Diluted EPS−$0.28$0.37$0.98$1.97$2.67$3.84$4.81$7.28$8.88$12.63$15.28$18.04
Diluted shares (average)31m36m40m37m38m38m38m34m32m32m30m29m
EBITDA276073110136179215298361475562634

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FTRE vs MEDPBIO vs MEDPBRKR vs MEDPMEDP vs QGEN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Medpace Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 23, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Medpace Holdings, Inc.